These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35706353)

  • 21. Portopulmonary hypertension in the current era of pulmonary hypertension management.
    Savale L; Guimas M; Ebstein N; Fertin M; Jevnikar M; Renard S; Horeau-Langlard D; Tromeur C; Chabanne C; Prevot G; Chaouat A; Moceri P; Artaud-Macari É; Degano B; Tresorier R; Boissin C; Bouvaist H; Simon AC; Riou M; Favrolt N; Palat S; Bourlier D; Magro P; Cottin V; Bergot E; Lamblin N; Jaïs X; Coilly A; Durand F; Francoz C; Conti F; Hervé P; Simonneau G; Montani D; Duclos-Vallée JC; Samuel D; Humbert M; De Groote P; Sitbon O
    J Hepatol; 2020 Jul; 73(1):130-139. PubMed ID: 32145258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.
    Boucly A; Savale L; Jaïs X; Bauer F; Bergot E; Bertoletti L; Beurnier A; Bourdin A; Bouvaist H; Bulifon S; Chabanne C; Chaouat A; Cottin V; Dauphin C; Degano B; De Groote P; Favrolt N; Feng Y; Horeau-Langlard D; Jevnikar M; Jutant EM; Liang Z; Magro P; Mauran P; Moceri P; Mornex JF; Palat S; Parent F; Picard F; Pichon J; Poubeau P; Prévot G; Renard S; Reynaud-Gaubert M; Riou M; Roblot P; Sanchez O; Seferian A; Tromeur C; Weatherald J; Simonneau G; Montani D; Humbert M; Sitbon O
    Am J Respir Crit Care Med; 2021 Oct; 204(7):842-854. PubMed ID: 34185620
    [No Abstract]   [Full Text] [Related]  

  • 23. Advances in targeted therapy for pulmonary arterial hypertension in children.
    Li L; Zhu X; Chen X; Gao J; Ding C; Zhang M; Ma S
    Eur J Pediatr; 2023 May; 182(5):2067-2076. PubMed ID: 36527480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
    Barnes H; Brown Z; Burns A; Williams T
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation.
    Calcaianu G; Canuet M; Schuller A; Enache I; Chaouat A; Kessler R
    Respiration; 2016; 91(1):9-17. PubMed ID: 26492415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival in systemic sclerosis associated pulmonary arterial hypertension in the current treatment era-results from a nationwide study.
    Sarı A; Satış H; Ayan G; Küçükşahin O; Kalyoncu U; Fidancı AA; Ayvalı MO; Ata N; Ülgü MM; Birinci Ş; Akdoğan A
    Clin Rheumatol; 2024 Jun; 43(6):1919-1925. PubMed ID: 38676757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
    Ruopp NF; Cockrill BA
    JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis.
    Sargent T; Tsang Y; Panjabi S; Funtanilla V; Germack HD; Gauthier-Loiselle M; Manceur AM; Cloutier M; Lefebvre P
    Adv Ther; 2023 Nov; 40(11):5037-5054. PubMed ID: 37728697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine.
    Douwes JM; Zijlstra WMH; Rosenzweig EB; Ploegstra MJ; Krishnan US; Haarman MG; Roofthooft MTR; Postmus D; Hillege HL; Ivy DD; Berger RMF
    Ann Am Thorac Soc; 2022 Feb; 19(2):227-237. PubMed ID: 34181866
    [No Abstract]   [Full Text] [Related]  

  • 32. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
    Kim NH; Hemnes AR; Chakinala MM; Highland KB; Chin KM; McLaughlin V; Zhao C; Narayan V; Farber HW
    J Heart Lung Transplant; 2021 Apr; 40(4):279-288. PubMed ID: 33526303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 34. Pulmonary arterial hypertension in a multi-ethnic Asian population: Characteristics, survival and mortality predictors from a 14-year follow-up study.
    Lim Y; Low TT; Chan SP; Teo TW; Jang JJ; Yip N; Kuntjoro I; Tay EL; Yip JW
    Respirology; 2019 Feb; 24(2):162-170. PubMed ID: 30180305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.
    Farber HW; Miller DP; Meltzer LA; McGoon MD
    J Heart Lung Transplant; 2013 Nov; 32(11):1114-22. PubMed ID: 24035189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Classification, diagnosis and treatment status of pulmonary hypertension from 2012 to 2019: a single center study in Yunnan province].
    Feng XL; Lu YB; Yang D; Xue Q; Zhang JL; Lin CR; Gan P; Zhang WH; Guang XF; Dai HL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Nov; 51(11):1188-1193. PubMed ID: 37963755
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
    Distler O; Ofner C; Huscher D; Jordan S; Ulrich S; Stähler G; Grünig E; Held M; Ghofrani HA; Claussen M; Lange TJ; Klose H; Rosenkranz S; Vonk-Noordegraaf A; Vizza CD; Delcroix M; Opitz C; Pausch C; Scelsi L; Neurohr C; Olsson KM; Coghlan JG; Halank M; Skowasch D; Behr J; Milger K; Remppis BA; Skride A; Jureviciene E; Gumbiene L; Miliauskas S; Löffler-Ragg J; Wilkens H; Pittrow D; Hoeper MM; Ewert R
    Rheumatology (Oxford); 2024 Apr; 63(4):1139-1146. PubMed ID: 37462520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension.
    Bajwa AA; Qureshi T; Shujaat A; Seeram V; Jones LM; Al-Saffar F; Cury JD
    J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):395-400. PubMed ID: 25613465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.
    Fauvel C; Liu Y; Correa-Jaque P; Kanwar MK; Vizza CD; Lin S; Benza RL
    Chest; 2023 Dec; 164(6):1518-1530. PubMed ID: 37356711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
    Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
    J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.